£1,200.00
5/5 from 131+ verified Google reviews
Individual tumour markers for cancer screening.
Trucheck Intelli Multi-Cancer Screening is a revolutionary blood-based test that detects over 70 types of solid tumors through the identification of circulating tumor cells (CTCs) in your bloodstream. Unlike traditional screening methods that focus on single cancer types, this comprehensive test provides whole-body cancer surveillance from a simple blood draw. Early detection is vital for successful cancer treatment and cure—late detection typically leads to intensive treatments, higher costs, and poorer outcomes.
The test identifies individual tumor cells and clusters of cells that have broken away from malignant tumors and are circulating in your bloodstream.
Trucheck can distinguish approximately 70 types of solid tumors, accounting for around 81% of all cancer cases and 84% of cancer-related deaths in Europe.
When CTCs are detected (positive result), the test provides tissue or organ of origin analysis with 96% accuracy.
Venous blood sample (25ml) drawn from arm
12-15 working days (approximately 2-3 weeks from sample collection to results)
If you can’t find the test you’re looking for, simply give us a call and our support team will guide you to the right option. We’re here to ensure you get the correct test quickly and confidently.
TruCheck Intelli is a proactive screening test for asymptomatic adults. If you currently have symptoms that could be caused by cancer — for example unexplained weight loss, persistent fatigue, a new lump, or a change in bowel habit — please see your GP or contact 111 rather than book a screening test. Symptoms need diagnostic investigation, not screening.
TruCheck Intelli is a straightforward blood-based screening test that fits around your life. Here is what happens from booking to receiving your report.
Choose a clinic appointment or a nurse-led home visit through our booking system.
A trained phlebotomist collects a 25ml venous blood sample. The draw itself takes around 10 to 15 minutes.
Your sample is sent under temperature-controlled conditions to the Datar Cancer Genetics laboratory for TruCheck Intelli analysis.
You receive a full written report within 12 to 15 working days of collection.
If further steps are needed, we help you take the report to your GP or a specialist for follow-up.
TruCheck Intelli detects circulating tumour cells (CTCs) associated with a broad range of solid tumour types. Publicly available Datar Cancer Genetics documentation currently references over 70 solid tumour types across the major organ systems.
TruCheck is designed for solid tumours only. It is not intended to detect:
If you have a specific personal or family cancer concern, please raise this with your GP or a specialist so the right test — screening or diagnostic — can be arranged.
TruCheck is designed for asymptomatic adults who want to add multi-cancer screening to their regular health monitoring. It is a proactive, private option that sits alongside — not in place of — the NHS cancer screening programmes and any care your GP provides.
TruCheck Intelli has been developed and validated in peer-reviewed clinical studies by Datar Cancer Genetics and independent researchers. Published data reports high specificity (the ability to correctly identify people who do not have cancer) and clinically useful sensitivity (the ability to correctly identify people who do).
A note on accuracy figures. Because sensitivity and specificity vary by study population, cancer type and stage, we prefer to walk you through the current published data at the point of booking rather than quote a single headline percentage. If you would like the underlying references before you book, please contact our team and we will share them.
What this means in practice is that TruCheck is designed to identify signals that warrant further investigation. It does not confirm or rule out cancer on its own — a positive result always needs to be followed up with a clinician, and a negative result does not eliminate all cancer risk.
Your written report will indicate whether the test has detected signals associated with circulating tumour cells, and where possible will suggest a likely tissue of origin.
No circulating tumour cell signals were detected in your sample at the time of testing. This is reassuring, but it does not guarantee absence of cancer.
You should continue to attend NHS screening (breast, bowel and cervical), stay alert to any new symptoms, and consider repeat multi-cancer screening on a schedule that suits your personal risk.
Signals associated with circulating tumour cells were detected. This is not a diagnosis of cancer — it is an indication that further clinical investigation is needed.
We will help you take the report to your GP or a specialist so that the appropriate follow-up tests (such as imaging or a biopsy) can be arranged promptly.
Book online at £1,200, or speak to our team first if you have questions.
We want you to make an informed choice. Every screening test has trade-offs, and being transparent about them is part of how we work.
| Limitation | What it means for you |
|---|---|
| Not a diagnostic test | TruCheck flags cell-level signals that warrant further investigation. It cannot, on its own, confirm or rule out cancer. |
| False positives are possible | Some people receive a positive result even though no cancer is present. This can lead to further tests and short-term anxiety. |
| False negatives are possible | Some cancers may not be picked up by the test, even at the time of sampling. |
| Not every cancer is included | The test targets solid tumours. It is not designed to detect blood cancers, brain tumours, or every rare cancer. |
| Does not replace NHS screening | TruCheck is an addition to — not a substitute for — NHS breast, bowel, cervical and other recommended screening. |
| Not for symptomatic people | If you have symptoms that could suggest cancer, a private screening test is the wrong pathway. Please see your GP. |
| Evidence is still evolving | The long-term impact of multi-cancer blood tests on cancer outcomes at a population level is still being studied in the UK. |
Swift Blood Tests offers TruCheck Intelli at a single transparent price. There are no hidden lab or courier fees.
| Included | Detail |
|---|---|
| Blood sample collection | Professional venous blood draw at a Swift Blood Tests clinic or by home visit (subject to postcode availability) |
| Sample handling | Temperature-controlled courier to the Datar Cancer Genetics laboratory |
| Laboratory analysis | TruCheck Intelli CTC analysis, including tissue-of-origin indication where applicable |
| Results report | Full written report within 12 to 15 working days of collection |
| Team support | Access to our team for practical questions about your booking and results process, before and after your test |
If you would like to speak to us before booking, call 01277 652067 or email enquiries@swiftbloodtests.co.uk.
Swift Blood Tests is a Care Quality Commission registered private provider, operating to UK healthcare standards.
Your sample is collected by trained, experienced phlebotomists — in clinic or at home.
Nurse-led home draws available across Essex, Bromley and Surrey — subject to postcode coverage.
131+ verified Google reviews across the Swift Blood Tests service.
£1,200 for the full service. No hidden lab or courier fees.
Head office in Basildon, Essex. UK-wide contact via phone and email.
TruCheck Intelli is a private blood-based screening test that looks for circulating tumour cells (CTCs) associated with over 70 types of solid tumours. It is designed for asymptomatic adults who want a proactive multi-cancer screening option alongside NHS screening.
TruCheck Intelli at Swift Blood Tests costs £1,200. This is a single transparent price covering the blood draw, temperature-controlled sample transport, laboratory analysis at Datar Cancer Genetics, and your full written report. There are no hidden lab or courier fees.
TruCheck and Galleri are two different multi-cancer detection technologies. TruCheck looks for circulating tumour cells (whole cancer cells in the bloodstream). Galleri looks for methylation signals from tumour DNA. Both are private tests in the UK and both require a follow-up clinical pathway if the result is positive. The right choice depends on cost, availability and the clinical picture — our team is happy to talk through the differences.
TruCheck Intelli has been validated in peer-reviewed clinical studies published by Datar Cancer Genetics and independent researchers. Because sensitivity and specificity vary by cancer type, stage and study population, we prefer to walk you through the current published data at the point of booking rather than quote a single headline percentage. If you would like the underlying references before you book, please contact our team.
No. TruCheck is an addition to — not a substitute for — NHS breast, bowel, cervical and other recommended screening programmes. Please continue to attend all NHS screening invitations, regardless of whether you have taken a private multi-cancer test.
TruCheck Intelli looks for signals associated with over 70 solid tumour types, including breast, lung, prostate, colorectal, pancreatic, liver, ovarian, head and neck, thyroid, melanoma, gastric, renal, bladder, cervical, uterine and oesophageal cancers, among others. It does not detect blood cancers, primary brain tumours or some rare cancer types.
TruCheck is designed for asymptomatic adults aged 40 and over who want additional proactive multi-cancer screening. It is commonly considered by people with a family history of cancer or those already engaged in preventative health checks. It is not suitable for people with current cancer symptoms, an active cancer diagnosis, or anyone undergoing cancer treatment.
A positive result is not a cancer diagnosis. It indicates that signals warranting further investigation have been detected. We will help you take your report to your GP or a specialist so that the appropriate follow-up — for example imaging or a biopsy — can be arranged.
A negative result means no circulating tumour cell signals were detected at the time of testing. This is reassuring, but it does not eliminate all cancer risk. You should continue to attend NHS screening, stay alert to new symptoms, and consider repeating multi-cancer screening on a schedule that suits your personal risk.
The blood draw itself takes around 10 to 15 minutes. Your written report is issued within 12 to 15 working days of the sample being collected.
Swift Blood Tests offers TruCheck Intelli via clinic appointments and nurse-led home visits across Essex, Bromley and Surrey. Book online from the panel above, call 01277 652067, or email enquiries@swiftbloodtests.co.uk.
Yes — nurse-led home visits are available across Essex, Bromley and Surrey, subject to postcode coverage. Please check your postcode at the booking stage.
No, you do not need a GP referral to book privately. We recommend keeping your GP informed of any private screening you take, so that any follow-up can be integrated into your NHS care.
TruCheck requires a standard venous blood draw of 25ml. The procedure carries the usual minor risks associated with any blood test (mild bruising or discomfort at the draw site) and no additional risks beyond that.
There is no single recommended interval. Frequency depends on your age, family history and personal risk. If you would like a view based on your circumstances, our team can talk you through what other patients typically choose.
